IMPORTANCE: Cendakimab selectively targets interleukin (IL)-13, a type 2 cytokine implicated in atopic dermatitis (AD) pathogenesis, by inhibiting binding to its receptors (IL13R-α1 and IL13R-α2). Proof-of-concept work in AD supports using cendakimab for type 2 inflammatory diseases. OBJECTIVE: To evaluate the efficacy and safety of cendakimab compared with placebo in patients with moderate to severe AD. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging clinical trial was conducted from May 2021 to November 2022. Adult patients with moderate to severe AD and inadequate response to topical medications were enrolled at 69 sites in 5 countries (US [n = 26], Japan [n = 17], Canada [n = 9], Poland [n = 9], and Czech Republic [n = 8]). Data were analyzed between April 25, 2023, and October 16, 2023. INTERVENTIONS: Patients were randomized (1:1:1:1) to receive subcutaneous cendakimab, 360 mg, every 2 weeks; 720 mg, every 2 weeks; 720 mg, once weekly; or placebo. MAIN OUTCOME AND MEASURE: Mean percentage change in Eczema Area and Severity Index scores from baseline to week 16. Hierarchical testing with multiplicity adjustment was performed for 720 mg, once weekly vs placebo, then 720 mg, every 2 weeks vs placebo, and then 360 mg, every 2 weeks vs placebo. RESULTS: Overall, 221 patients were randomized, and 220 received study drug (95 women [43%]; mean [SD] age, 37.7 [13.9] years; 720 mg, once weekly [54 (24%)]; 720 mg, every 2 weeks [55 (25%)]; 360 mg, every 2 weeks [55 (25%)]; placebo [56 (26%)]). The primary efficacy end point was met for cendakimab, 720 mg, once weekly vs placebo (-84.4 vs -62.7; P = .003) but missed statistical significance for 720 mg, every 2 weeks (-76.0 vs -62.7; P = .06). The treatment effect for 360 mg, every 2 weeks (-16.3; nominal P = .03 vs placebo) was comparable with 720 mg, once weekly (-21.8); however, significance was not claimed because the hierarchical testing sequence was interrupted. Of patients with treatment-emergent adverse events leading to discontinuation, 4 (7.4%) received 720 mg, once weekly; 2 (3.6%) 720 mg, every 2 weeks; 1 (1.8%) 360 mg, every 2 weeks; and 2 (3.6%) placebo. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial indicated that cendakimab was effective, generally safe, and well-tolerated in patients with moderate to severe AD. The primary end point was met with a significant reduction in Eczema Area and Severity Index scores with 720 mg, once weekly at week 16. Cendakimab demonstrated progressive AD improvement at all doses during 16 weeks of treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04800315.

Bristol Myers Squibb Princeton New Jersey

CCR Czech Prague Prague Czech Republic

Fukuoka University Faculty of Medicine Fukuoka Japan

George Washington University School of Medicine and Health Sciences Washington DC

Icahn School of Medicine Mount Sinai New York New York

Klinika Ambroziak Dermatologia Lazarski University Warsaw Poland

Nagoya City University Graduate School of Medical Sciences Nagoya Japan

Oregon Medical Research Center Portland Oregon

Skin Specialists P C Omaha Nebraska

Teikyo University School of Medicine Tokyo Japan

University of Manitoba Winnipeg Manitoba Canada

University of Toronto Toronto Ontario Canada

See more in PubMed

Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595-605. doi:10.1016/j.clindermatol.2018.05.007 PubMed DOI

Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-279.e3. doi:10.1016/j.jaad.2017.04.019 PubMed DOI

Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56-66. doi:10.1038/jid.2014.325 PubMed DOI

Yu SH, Attarian H, Zee P, Silverberg JI. Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis. 2016;27(2):50-58. doi:10.1097/DER.0000000000000161 PubMed DOI

Chandra RK, Lin D, Tan B, et al. . Chronic rhinosinusitis in the setting of other chronic inflammatory diseases. Am J Otolaryngol. 2011;32(5):388-391. doi:10.1016/j.amjoto.2010.07.013 PubMed DOI PMC

Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A; ISAAC Phase Three Study Group . The International Study of Asthma and Allergies in Childhood (ISAAC) -hase three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73-85. doi:10.1016/j.aller.2012.03.001 PubMed DOI

Doucet-Ladevèze R, Holvoet S, Raymond F, et al. . Transcriptomic analysis links eosinophilic esophagitis and atopic dermatitis. Front Pediatr. 2019;7:467. doi:10.3389/fped.2019.00467 PubMed DOI PMC

Chu DK, Schneider L, Asiniwasis RN, et al. . Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274-312. PubMed

Ariëns LFM, Bakker DS, van der Schaft J, Garritsen FM, Thijs JL, de Bruin-Weller MS. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159-170. doi:10.1177/2040622318773686 PubMed DOI PMC

Kelly KA, Perche PO, Feldman SR. Therapeutic potential of tralokinumab in the treatment of atopic dermatitis: a review on the emerging clinical data. Clin Cosmet Investig Dermatol. 2022;15:1037-1043. doi:10.2147/CCID.S267217 PubMed DOI PMC

Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729-749. doi:10.1007/s13555-023-00892-5 PubMed DOI PMC

Furue M, Ulzii D, Nakahara T, et al. . Implications of IL-13Rα2 in atopic skin inflammation. Allergol Int. 2020;69(3):412-416. doi:10.1016/j.alit.2020.01.005 PubMed DOI

Tsoi LC, Rodriguez E, Degenhardt F, et al. . Atopic dermatitis is an IL-13–dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018 PubMed DOI PMC

Ulzii D, Kido-Nakahara M, Nakahara T, et al. . Scratching counteracts IL-13 signaling by upregulating the decoy receptor IL-13Rα2 in keratinocytes. Int J Mol Sci. 2019;20(13):3324. doi:10.3390/ijms20133324 PubMed DOI PMC

Bristol-Myers Squibb . Bristol-Myers Squibb to acquire Celgene to create a premier innovative biopharma co. Accessed March 1, 2024. https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Acquire-Celgene-to-Create-a-Premier-Innovative-Biopharma-Company/default.aspx

World Medical Association . WMA Declaration of Helsinki—ethical principles for medical research involving human subjects. Accessed March 6, 2024. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

Dixon JR Jr. The International Conference on Harmonization good clinical practice guideline. Qual Assur. 1998;6(2):65-74. doi:10.1080/105294199277860 PubMed DOI

Simpson E, Bissonnette R, Eichenfield LF, et al. . The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839-846. doi:10.1016/j.jaad.2020.04.104 PubMed DOI

Yosipovitch G, Reaney M, Mastey V, et al. . Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761-769. doi:10.1111/bjd.17744 PubMed DOI PMC

de Bruin-Weller M, Thaçi D, Smith CH, et al. . Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101. doi:10.1111/bjd.16156 PubMed DOI

Simpson EL, Bieber T, Guttman-Yassky E, et al. ; SOLO 1 and SOLO 2 Investigators . Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348. doi:10.1056/NEJMoa1610020 PubMed DOI

Thaçi D, Simpson EL, Beck LA, et al. . Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40-52. doi:10.1016/S0140-6736(15)00388-8 PubMed DOI

Tofte SJ, Papp K, Sadick N, et al. . Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 clinical trials. J Am Assoc Nurse Pract. 2018;30(9):529-541. doi:10.1097/JXX.0000000000000088 PubMed DOI

Wollenberg A, Beck LA, de Bruin Weller M, et al. . Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453-465. doi:10.1111/bjd.20810 PubMed DOI

Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. ; ECZTRA 1 and ECZTRA 2 Study Investigators . Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-449. doi:10.1111/bjd.19574 PubMed DOI PMC

Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. . Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411-420. doi:10.1001/jamadermatol.2020.0079 PubMed DOI PMC

Simpson EL, Paller AS, Siegfried EC, et al. . Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44-56. doi:10.1001/jamadermatol.2019.3336 PubMed DOI PMC

Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54-62. doi:10.1111/all.13954 PubMed DOI

Wollenberg A, Howell MD, Guttman-Yassky E, et al. . Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135-141. doi:10.1016/j.jaci.2018.05.029 PubMed DOI

Lytvyn Y, Gooderham M. Targeting interleukin 13 for the treatment of atopic dermatitis. Pharmaceutics. 2023;15(2):568. doi:10.3390/pharmaceutics15020568 PubMed DOI PMC

Ferreira S, Torres T. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs Context. 2020;9:2020-2022-2023. doi:10.7573/dic.2020-2-3 PubMed DOI PMC

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. . Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459-473. doi:10.1111/bjd.17869 PubMed DOI PMC

Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol. 2018;178(5):1220. doi:10.1111/bjd.16330 PubMed DOI

Bakker DS, Ariens LFM, van Luijk C, et al. . Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180(5):1248-1249. doi:10.1111/bjd.17538 PubMed DOI PMC

Ravn NH, Ahmadzay ZF, Christensen TA, et al. . Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;85(2):453-461. doi:10.1016/j.jaad.2020.11.037 PubMed DOI

Bachert C, Mannent L, Naclerio RM, et al. . Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469-479. doi:10.1001/jama.2015.19330 PubMed DOI

Castro M, Corren J, Pavord ID, et al. . Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496. doi:10.1056/NEJMoa1804092 PubMed DOI

Hirano I, Dellon ES, Hamilton JD, et al. . Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111-122.e10. doi:10.1053/j.gastro.2019.09.042 PubMed DOI

Andreasen TH, Christensen MO, Halling AS, Egeberg A, Thyssen JP. Placebo response in phase 2 and 3 trials of systemic and biological therapies for atopic dermatitis-a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(6):1143-1150. doi:10.1111/jdv.16163 PubMed DOI

Lee HH, Patel KR, Rastogi S, et al. . Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(1):62-71. doi:10.1016/j.jaad.2019.05.102 PubMed DOI

Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756-768. doi:10.1111/exd.13911 PubMed DOI PMC

Silverberg JI, Barbarot S, Gadkari A, et al. . Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. doi:10.1016/j.anai.2020.12.020 PubMed DOI

See more in PubMed

ClinicalTrials.gov
NCT04800315